Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases.
| Τίτλος | Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases. |
| Publication Type | Journal Article |
| Year of Publication | 2017 |
| Authors | Zarogoulidis, P., Chinelis P., Athanasiadou A., Tsiouda T., Trakada G., Kallianos A., Veletza L., Hatzibougias D., Mihalopoulou E., Goupou E., Kosmidis C., Sardeli C., Huang H., & Hohenforst-Schmidt W. |
| Journal | Respir Med Case Rep |
| Volume | 22 |
| Pagination | 101-105 |
| Date Published | 2017 |
| ISSN | 2213-0071 |
| Abstract | In the past decade novel agents are on the market for non-small cell lung cancer adenocarcinoma based on pharmacogenomics. The epidermal growth factor receptor mutation, anaplastic lymphoma kinase and programmed death-ligand 1 investigation is necessary in the everyday clinical practice for the oncologic patient. Immunotherapy is nowadays the novel therapy for advanced stage non-small cell lung cancer with two agents nivolumab and pembrolizumab. In the current case series we will present adverse effects from our centers and comment on the treatment and follow-up of the patients. |
| DOI | 10.1016/j.rmcr.2017.07.004 |
| Alternate Journal | Respir Med Case Rep |
| PubMed ID | 28752057 |
| PubMed Central ID | PMC5519224 |
